National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Best Pharmaceuticals for Children Act (BPCA) banner National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Best Pharmaceuticals for Children Act (BPCA) banner
      
BPCA Home
 
About BPCA
 
Clinical Studies
 
Literature and Data Resources
 
BPCA Collaborative Efforts and Outreach Activities
 
Contact BPCA Program Staff
 
line
NICHD Home
Health and Human Development Information
Research
Funding for Research and Training
News and Media
About NICHD

Best Pharmaceuticals for Children Act (BPCA) Activities at NICHD

The Best Pharmaceuticals for Children Act (BPCA) Program is a major activity for the Obstetric and Pediatric Pharmacology Branch (OPPB), a component of the Center for Research for Mothers and Children at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

OPPB is responsible for developing and supporting a comprehensive national research and training effort to increase the knowledge base for understanding how to appropriately treat disease during pregnancy, infancy, and childhood using pharmaceuticals that are appropriately tested within their target populations. NICHD activities related to BPCA are intended to improve pediatric drug therapeutics through preclinical and clinical testing that lead to drug labeling change.


Updates

Outcome Measures for Clinical Trials with Children with Fragile X Syndrome
May 8–9, 2008
Hyatt Regency Bethesda
Bethesda, Maryland

2008 BPCA Prioritization Scientific Meeting
June 30–July 1, 2008
Fishers Lane Conference Center
Rockville, Maryland

2008 Biodefense Advisory Group Meeting
September 8–9, 2008
EPN Conference Center
Rockville, MD




NICHD Home |   |   |  NICHD Disclaimer |  Accessibility |  Top of Page